Ignore the Analysts<br />By Rev Shark<br />RealMoney.com Contributor<br />6/19/2008 9:20 AM EDT <br /><br />You know, sometimes, when they say you're ahead of your time, it's just a polite way of saying you have a real bad sense of timing. <br /><br />--George McGovern <br /><br />One of the ironies of Wall Street is that as the technical condition of the major indices deteriorates, the louder the calls that a turning point is near will become. Wall Street is full of people who hate the idea of respecting a trend. The masses are always considered to be ignorant yokels who never get it right. The brilliant analysts with contrary opinions are considered, by the media, to be unusually insightful when the truth is, most of them have such poor timing that the recommendations they make are useless. <br /><br />The fact of the matter is that the crowd of average investors is right most of the time. If you stick with the prevailing trend, you will usually make out pretty well. It is only at extremes that the crowd is wrong and trying to determine exactly when sentiment is so extreme that it signals a major turning point is an art, not a science. <br /><br />I bring this up because as the "Worst is Over" rally off the March lows fails and turns into nothing more than a classic bear-market bounce, there are going to be plenty of market pundits once again calling for another such rally. They are going to urge you to hurry up and buy because the bottom is almost here, and if you aren't fully invested, you will be left out. <br /><br />That is baloney. The market is falling into a downtrend, and while we may see some countertrend bounces and rallies, like we had last week, there is nothing to indicate that a bottom is near. So, many folks get excited every time there is a slight bounce within a downtrend, and as a result, they want to hurry up and buy. <br /><br />Keep in mind that if stocks are in a downtrend, it takes some time for the charts to improve and be buyable. You might be able to trade within a downtrend for bounces, but stocks worthy of buying for the longer term will need more than a bounce before they are buyable. <br /><br />Making money in the market is all about timing. Unfortunately, Wall Street has an oversupply of folks who make a living by constantly calling for turning points in the market. Although many eventually get it right, most have such poor timing that their predictions prove useless. <br /><br />This market is now mired in a downtrend. Respect that fact and ignore those who are anxious to call for a turning point. The crowd is a lot smarter than you think, and trends almost always last longer than seems reasonable. <br /><br />We have some minor strength to start the day as oil pulls back a little, and the news wires are mostly quiet. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />USNA +14.0%, CWST +8.4% (also upgraded to Overweight at JPMorgan), HWAY +5.6%... M&A news: AHG +26.4% (to be acquired by affiliate of the Blackstone Group; shareholders to receive $21.00 per share in all-cash)... Other news: ESLR +11.8% (signs two new sales contracts totaling ~$600 mln), IMAX +8.3% (still checking), LLNW +5.2% (Judge says Limelight ban 'premature' - Reuters.com), POWR +3.0% (deepens utility relationships and diversifies revenue base with new business awards; co has been awarded $10 mln in new business), MT +3.0% (still checking), FRX +2.7% (announces "positive results" from Phase III clinical studies of Ceftaroline for the treatment of complicated skin and skin structure infections), EP +1.7% and SWN +1.7% (Cramer makes positive comments on MadMoney), SGMO +1.6% (Dow AgroSciences announces early exercise of option for commercial license with Sangamo BioSciences for plants)... Analyst upgrades: KMX +2.4% (upgraded to Market Perform at Wachovia), AIG +1.9% (upgraded to Buy at Citigroup), TOT +1.7% (upgraded to Buy at Goldman - DJ), RDC +1.2% (initiated with a Buy at Jesup & Lamont).<br /><br />Allapoole avanevad:<br /><br />CVH -21.3% (also downgraded to Market Perform at Wachovia), AMSWA -5.7%, CC -3.8%, PRGS -1.4% (light volume)... Select China names showing weakness with Hang Seng closing -2.3% as investors were disappointed by lack of mkt-boosting measures from Beijing: ACH -4.2% (was second biggest percentage loser on the Hang Seng Index with Macquarie Group cutting co's 2008 EPS estimate by 13% on higher production costs and lower prices), LMC -2.5%, LFC -1.9%, SNP -1.3%... Select European financials showing weakness: UBS -4.1% (Swiss central bank demands UBS, Credit Suisse beef up capital - Reuters; also coverage resumed with Neutral from Outperform at Credit Suisse), CS -2.0% (Swiss central bank demands UBS, Credit Suisse beef up capital - Reuters), LYG -1.9%, BCS -1.4%, DB -1.1%... Select healthcare stocks trading lower following disappointing CVH guidance: UNH -11.2%, WCG -6.9%, WLP -5.7%, AET -4.9% (still down despite co reaffirming Q2 and Y08 guidance), HUM -4.9%, CI -3.8%, AGP -3.7%, CNC -3.1%, MHS -2.1% (downgraded to Neutral at UBS)... Other news: HUN -33.4% (Hexion files suit alleging that transaction with Huntsman is no longer viable; also downgraded to Underperform at Jefferies), LEAP -7.5% (announces proposed private placement of $200 mln in Convertible Senior Notes and of $200 mln in Senior Notes), CSE -4.2% (announces it plans a public offering of approx 30 mln shares of common stock), XMSR -3.7% (still checking), NOK -2.6% (price estimate cut overnight to 14.5 euros from 17 euros at Societe Generale SA), ASML -2.2% (still checking), CEDC -1.2% (announces common stock offering of 3.125 mln shares), GOOG -1.1% (still checking), VRUS -1.0% (files for mixed securities shelf offering of up to $100 mln)... Analyst downgrades: SYNA -3.8% (downgraded to Market Perform at Oppenheimer), CMC -1.8% (downgraded to Hold at Citigroup), PSD -1.7% (downgraded to Sell at Soleil), CAKE -1.6% (downgraded to Neutral at UBS).